SEC Filing Summary: Platform Specialty Products Corporation
Business Context and Reporting Period
This Form 8-K was filed by Platform Specialty Products Corporation on November 2, 2015. The report addresses Item 8.01 (Other Events) regarding the proposed acquisition of Alent plc (the "Alent Acquisition"). The filing provides unaudited pro forma financial information as of June 30, 2015, and for the periods ended June 30, 2015, and December 31, 2014.
Key Financial Metrics
The filing does not contain actual historical financial results for Platform Specialty Products Corporation. Instead, it references unaudited pro forma condensed consolidated balance sheets and statements of operations attached as Exhibit 99.1. These pro forma figures give effect to:
- The proposed Alent Acquisition (valued at approximately $2.1 billion based on a GBP/USD rate of 1.5517).
- Related financings.
- The acquisition of the Chemtura AgroSolutions business.
- The acquisition of Arysta LifeScience Limited.
Specific revenue, profit, cash flow, margin, debt, or liquidity figures are not provided in the text of this filing; they are contained within the referenced Exhibit 99.1.
Material Changes
The primary material change disclosed is the progression of the Alent Acquisition, previously announced on July 13, 2015. The transaction is structured as a cash and stock deal under a UK law governed scheme of arrangement. The filing notes that the scheme document was sent to Alent shareholders on August 17, 2015.
Outlook, Risks, and Management Commentary
Management explicitly states that there can be no assurance that the Alent Acquisition will close, be completed in the anticipated timeframe, or be completed on the currently anticipated terms. The pro forma information is intended to illustrate the financial impact of the proposed transactions should they be completed.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma financial statements (balance sheet and operations) to assess the combined entity's financial position.
- Verify the status of the UK scheme of arrangement and shareholder approval for the Alent Acquisition.
- Confirm the final exchange rate used for the $2.1 billion valuation, as the filing cites a rate from July 10, 2015.
- Assess the financing terms required to complete the Alent, Chemtura, and Arysta acquisitions.